Lilly shows more positive Crohn's data for its IL-23 inhibitor as it continues to chase down rivals
About a year and a half after presenting positive topline results in Crohn’s disease, Eli Lilly gave its experimental IL-23 anti-inflammatory mirikizumab a boost Monday with new data.
The fresh info comes from the Phase II study and is a 52-week follow-up of the original trial. Mirikizumab showed that, after the initial 12-week period, patients who continued treatment for another 40 weeks saw further improvement in endoscopic response and Patient-Reported Outcomes remission.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
